ExelixisEXEL

• Phase 3XL092·아테졸리주맙 전이성 대장암 병용 임상진행 중Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
  33%
• Phase 2재발·진행성 뇌수막종 환자 대상 잔잘린티닙 임상모집 중A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
  62%
• Phase 2잔잘린티닙 진행성 신경내분비종양 비교 치료 임상모집 중Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
  74%
• Phase 1재발·전이성 고형암 대상 XB628 치료 임상모집 중A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
  76%
• Phase 1고형암 대상 잔잘린티닙 면역항암 병용 임상모집 중Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
  53%
• Phase 1XB010 고형암 치료 임상모집 중Study of XB010 in Subjects With Solid Tumors
  72%
• Phase 3엑셀릭시스 기존 임상 참여 환자 대상 장기 추적 연구시작 전Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
  97%
• Phase 1XB371 진행성 및 전이성 고형암 치료 임상모집 중A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
  78%
• Phase 3카보잔티닙·아테졸리주맙 병용 전이성 전립선암 임상진행 중Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
  99%
• Phase 3카보잔티닙·아테졸리주맙 병용 진행성 간암 1차 치료 임상진행 중Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
  85%
• Phase 3카보잔티닙 방사성요오드 불응성 갑상선암 치료 임상진행 중A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
  99%
• Phase 3진행성 신장암 카보잔티닙 3제 병용 치료 임상진행 중Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  35%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.